| Symbol | AEMD |
|---|---|
| Name | AETHLON MEDICAL INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Surgical & Medical Instruments & Apparatus |
| Address | 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA 92121 |
| Telephone | 619-941-0360 |
| Fax | — |
| — | |
| Website | https://www.aethlonmedical.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000882291 |
| Description | Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment. Additional info from NASDAQ: |
New Form DEFA14A - AETHLON MEDICAL INC <b>Filed:</b> 2026-09-04 <b>AccNo:</b> 0001683168-26-006969 <b>Size:</b> 54 KB
Read moreNew Form PRE 14A - AETHLON MEDICAL INC <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001683168-26-006654 <b>Size:</b> 5 MB
Read moreAethlon Medical Reports Q1 Fiscal 2027 Results and Progress onHemopurifier® Program
Read moreAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Read moreNew Form SCHEDULE 13G/A - AETHLON MEDICAL INC <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001213900-26-088823 <b>Size:</b> 10 KB
Read moreAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Read moreAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Read moreAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial EvaluatingHemopurifier®
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04595903 | Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® D… | Na | COVID-19 | Terminated | 2022-06-01 | 2022-11-14 | ClinicalTrials.gov |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Na | Squamous Cell Carcinoma of the Head and Neck | Terminated | 2020-10-22 | 2022-11-14 | ClinicalTrials.gov |
| NCT02215902 | Safety Study of the Aethlon Hemopurifier | Na | End Stage Renal Disease | Terminated | 2014-12-01 | 2017-03-10 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pembrolizumab 200mg IV | Other | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Hemopurifier | Other | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Affinity plasmapheresis | Other | Approved | End Stage Renal Disease | TERMINATED | NCT02215902 |
| Hemopurifier | Other | Approved | COVID-19 | TERMINATED | NCT04595903 |
| Pembrolizumab 200mg IV | DRUG | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Hemopurifier | DEVICE | Approved | COVID-19 | TERMINATED | NCT04595903 |
| Affinity plasmapheresis | DEVICE | Approved | End Stage Renal Disease | TERMINATED | NCT02215902 |